In discussions about genomic medicine, it is easy to assume that established technologies will eventually be replaced by newer ones. Fluorescence in situ hybridization (FISH) is sometimes viewed through this lens. The continued expansion of next-generation sequencing (NGS), molecular profiling, and other high-resolution genomic methods has led some to question whether FISH will remain clinically relevant in the future.
From my perspective, this framing overlooks an important reality: FISH has evolved alongside these technologies rather than being displaced by them. In fact, what we see is that the value of FISH today lies not in competing with broader genomic approaches, but in providing fast, focused, and clinically actionable genomic information that complements other diagnostic methods.
FISH emerged around the 1980s, following on from chromosome analysis techniques such as radioisotope labelling, and represented a significant advance in the ability to visualize specific genomic abnormalities directly within cells. In its simplest form, FISH is the process of using fluorescence-labelled DNA probes to hybridize to targeted chromosomal regions, allowing copy number changes, rearrangements, fusions, amplifications, and deletions to be detected in metaphase chromosomes or interphase nuclei.
The simplicity of FISH lies in its ability to provide targeted genetic information without the need for lengthy cell culture. This feature helped establish FISH as an important component of diagnostic cytogenetics. As genomic technologies expanded, laboratories gained access to increasingly comprehensive methods for interrogating the genome. Rather than competing with these broader approaches, FISH cemented its specialized role, focused on answering defined clinical questions quickly and reliably.
Today its usage is widespread. Recent surveys showed that more than 80 percent of CAP-accredited laboratories in the United States carried out FISH testing between 2017 and 2020. In a similar timeframe in France, constitutional FISH testing was reported to have increased from 14,053 to 18,464 examinations per year.
Modern hemato-oncology diagnosis increasingly relies on integrated assessment. According to the WHO Classification of Haematolymphoid Tumours, accurate diagnosis requires the integration of morphological, immunophenotypic, molecular, and cytogenetic information. FISH remains one of the specialized diagnostic techniques supporting this integrated approach.
In constitutional genetics, FISH remains a primary diagnostic and genomic characterization tool. FISH probes continue to be used in both modern genomic and less technologically advanced laboratories to identify specific chromosomal abnormalities, including microdeletions, aneuploidies, and cryptic sub-telomeric translocations, which can aid a constitutional genetic diagnosis.
The strength of FISH is its ability to answer specific clinical questions quickly and reliably. In many hematological malignancies, recurrent chromosomal abnormalities have established diagnostic, prognostic, or therapeutic significance. For example, in suspected acute promyelocytic leukemia (APML), FISH can rapidly detect the PML::RARA fusion, providing clinically important information in a disease where timely diagnosis and treatment initiation are critical.
FISH can identify these abnormalities rapidly and can be used alongside morphology, flow cytometry, karyotyping, PCR, and sequencing within a comprehensive diagnostic work-up. The technique is particularly valuable when rapid information is required, when karyotyping is unsuccessful, or when only limited material is available.
Importantly, FISH continues to feature in numerous disease pathways within the NHS England National Genomic Test Directory, including several forms of leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and some lymphoma subtypes.
One reason FISH has remained clinically relevant is that modern laboratories rarely rely on a single technology. The 5th edition of the WHO Classification of Haematolymphoid Tumours places increasing emphasis on molecularly defined disease entities and therapeutically actionable biomarkers, but also reinforces the need for integrated diagnostic assessment. In practice, this means laboratories frequently combine cytogenetic, molecular, and immunophenotypic data to reach a final diagnosis.
Rather than replacing FISH, technologies such as NGS have expanded the range of questions that laboratories can answer. FISH remains valuable as a targeted assay, an orthogonal method for confirming findings, and a means of rapidly assessing clinically significant abnormalities within established diagnostic pathways. In my view, one of the most important lessons from the past two decades is that new technologies complement existing approaches far more often than replacing them.
The future of FISH is likely to be shaped by two parallel trends. The first is precision medicine. As targeted therapies become increasingly important across oncology, accurate identification of clinically actionable genomic abnormalities remains essential for treatment selection. Targeted cytogenetic testing remains an important contributor to those decisions, as evidenced by the range of FDA-approved FISH companion diagnostics in use today.
The second trend is operational evolution. Automated image acquisition, digital review workflows, and advanced analysis tools are increasingly supporting standardization and efficiency within cytogenetics laboratories. These developments do not change the underlying biological value of FISH. Instead, they help laboratories deliver results more consistently while supporting growing diagnostic demand.
In conclusion, FISH is not a legacy technique waiting to be replaced. Rather, its clinical role has evolved from that of a primary genomic testing method to becoming a highly focused component of integrated diagnostic care. Evidence from contemporary clinical practice, international guidelines, and the WHO classification framework all point towards the same conclusion: modern hemato-oncology depends on combining multiple diagnostic modalities rather than selecting a single winner.
As classifications become more genetically informed and precision medicine continues to advance, FISH will remain an important part of the diagnostic toolkit. Its future lies in providing targeted, clinically actionable information where speed, reliability, and established clinical utility remain essential.
